TIQUIZIUM

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H24NS2
Molecular Weight	330.531
Optical Activity	( + / - )
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	1

SHOW SMILES / InChI

Structure Search

SMILES

C[N@+]12CCCC[C@@H]1CCC(C2)=C(C3=CC=CS3)C4=CC=CS4

InChI

InChIKey=ZGSDGGRVFIYKKE-OXQOHEQNSA-N

InChI=1S/C19H24NS2/c1-20-11-3-2-6-16(20)10-9-15(14-20)19(17-7-4-12-21-17)18-8-5-13-22-18/h4-5,7-8,12-13,16H,2-3,6,9-11,14H2,1H3/q+1/t16-,20-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8839659 | http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=2247

Tiquizium is an antispasmodic agent used to treat disorders of the gastrointestinal, biliary, and urinary systems. Tiquizium is available commercially in Japan for the treatment of gastrointestinal disease. Tiquizium shows anti-muscarinic action to improve convulsion and hypermobility of intestinal smooth muscle. It is usually used to treat convulsion and hypermobility in gastritis, gastric ulcer, duodenal ulcer, enteritis, irritable bowel syndrome, gallbladder disease, biliary tract disease and urolithiasis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Muscarinic acetylcholine receptor M1 168 Target ID: CHEMBL216 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898 \| https://www.ncbi.nlm.nih.gov/pubmed/8839659 \| https://www.ncbi.nlm.nih.gov/pubmed/3656779	Antagonist 2849	4.1 nM [Ki]
Muscarinic acetylcholine receptor M2 121 Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898 \| https://www.ncbi.nlm.nih.gov/pubmed/8839659 \| https://www.ncbi.nlm.nih.gov/pubmed/3656779	Antagonist 2849	4.0 nM [Ki]
Muscarinic acetylcholine receptor M3 160 Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898 \| https://www.ncbi.nlm.nih.gov/pubmed/8839659 \| https://www.ncbi.nlm.nih.gov/pubmed/3656779	Antagonist 2849	2.8 nM [Ki]
Muscarinic acetylcholine receptor M4 87 Target ID: CHEMBL1821 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898 \| https://www.ncbi.nlm.nih.gov/pubmed/8839659 \| https://www.ncbi.nlm.nih.gov/pubmed/3656779	Antagonist 2849	3.6 nM [Ki]
Muscarinic acetylcholine receptor M5 63 Target ID: CHEMBL2035 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898 \| https://www.ncbi.nlm.nih.gov/pubmed/8839659 \| https://www.ncbi.nlm.nih.gov/pubmed/3656779	Antagonist 2849	8.2 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Gastritis 46 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2895054	Primary	Approved 8583	Thiaton Approved Use Thiaton is usually used to treat convulsion and hypermobility in gastritis, gastric ulcer, duodenal ulcer, enteritis, irritable bowel syndrome, gallbladder disease, biliary tract disease and urolithiasis.
Gastric ulcer 74 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2895054 https://www.ncbi.nlm.nih.gov/pubmed/2895053	Primary	Approved 8583	Thiaton Approved Use Thiaton is usually used to treat convulsion and hypermobility in gastritis, gastric ulcer, duodenal ulcer, enteritis, irritable bowel syndrome, gallbladder disease, biliary tract disease and urolithiasis.
Urolithiasis 3 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=2247	Primary	Approved 8583	Thiaton Approved Use Thiaton is usually used to treat convulsion and hypermobility in gastritis, gastric ulcer, duodenal ulcer, enteritis, irritable bowel syndrome, gallbladder disease, biliary tract disease and urolithiasis.
Irritable bowel syndrome 61 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=2247	Primary	Approved 8583	Thiaton Approved Use Thiaton is usually used to treat convulsion and hypermobility in gastritis, gastric ulcer, duodenal ulcer, enteritis, irritable bowel syndrome, gallbladder disease, biliary tract disease and urolithiasis.
Biliary tract diseases 11 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=2247	Primary	Approved 8583	Thiaton Approved Use Thiaton is usually used to treat convulsion and hypermobility in gastritis, gastric ulcer, duodenal ulcer, enteritis, irritable bowel syndrome, gallbladder disease, biliary tract disease and urolithiasis.

PubMed

Title	Date	PubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010-12	21818443
Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer.	2008-05	18221252
Inhibitory effects of ramosetron, a potent and selective 5-HT3-receptor antagonist, on conditioned fear stress-induced abnormal defecation and normal defecation in rats: comparative studies with antidiarrheal and spasmolytic agents.	2008-02	18296863
Pharmacological profile of ramosetron, a novel therapeutic agent for IBS.	2007-02	17323187

Patents

Sample Use Guides

In Vivo Use Guide

In general, for adults, take 5 to 10 mg of the active ingredient at a time, three times a day. The dosage may be adjusted according to the age and symptoms. This preparation contains 10 mg of the active ingredient in a capsule.

Route of Administration: Oral

In Vitro Use Guide

Tiquizium (1 x 10(-6) - 1x10(-5)g/ml) increased transmural stimulation (TM contraction) and/or resting tone (1 x 10(-5)g/ml) in isolated guinea pig urinary bladder.

Name

Type

Language

TIQUIZIUM

Common Name

English

TIQUIZIUM CATION

Preferred Name

English

2H-QUINOLIZINIUM, 3-(DI-2-THIENYLMETHYLENE)OCTAHYDRO-5-METHYL-, TRANS-

Systematic Name

English

Tiquizium [WHO-DD]

Common Name

English

TIQUIZIUM ION

Common Name

English

Code System Code Type Description

CAS

149755-23-7